Log in to your Inderes Free account to see all free content on this page.

Moberg Pharma

8.105

SEK

+2.47 %

Less than 1K followers

MOB

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

+2.47%

+6.3%

-15.13%

-20.3%

-27.44%

-76.51%

-50.04%

-89.19%

-86.43%

Moberg Pharma is a Swedish pharmaceutical company focused on the commercialization of proprietary medicines based on proven substances. The company mainly works in nail fungus, where Moberg Pharma is developing a new external treatment. The company has agreements with commercial partners on site in Europe and Asia, among other places. The head office is in Bromma.

Market cap

388.07M SEK

Turnover

490.77K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

13.5.

2025

Interim report Q1'25

22.5.

2025

General meeting '25

12.8.

2025

Interim report Q2'25

All

Press releases

ShowingAll content types

Regulatory press release4/22/2025, 6:00 AM

Notice of Annual General Meeting in Moberg Pharma AB (publ)

Regulatory press release4/11/2025, 6:00 AM

Moberg Pharma's Annual report for 2024

Press release2/12/2025, 9:37 AM

Redeye: Moberg Pharma Q4’2024 - All eyes on the European market

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release2/11/2025, 7:00 AM

Moberg Pharma Year-end report 2024

Press release2/3/2025, 7:00 AM

Moberg Pharma: Terclara (MOB-015) is now being launched in Norway

Regulatory press release12/18/2024, 7:00 AM

Moberg Pharma: New terbinafine supplier secured

Regulatory press release12/10/2024, 7:30 PM

Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU

Press release11/13/2024, 4:55 PM

Redeye: Moberg Pharma Q3’2024 - Launch in focus awaiting top line data

Regulatory press release11/12/2024, 7:00 AM

Moberg Pharma's Interim report January - September 2024

Regulatory press release11/8/2024, 7:30 AM

Moberg Pharma's Nomination Committee appointed

Regulatory press release9/13/2024, 6:00 AM

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Press release8/14/2024, 6:38 AM

Redeye: Moberg Pharma - The Swedish market leader

Regulatory press release8/13/2024, 6:00 AM

Moberg Pharma's interim report January - June 2024

Regulatory press release7/31/2024, 6:00 AM

New number of shares and votes in Moberg Pharma AB (publ)

Regulatory press release6/28/2024, 6:00 AM

New number of shares and votes in Moberg Pharma AB (publ)

Regulatory press release6/24/2024, 3:35 PM

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Regulatory press release6/17/2024, 6:00 AM

The last day for trading in Moberg Pharma's warrants of series 2023:1 (TO 2) is today, June 17[th], 2024

Regulatory press release6/11/2024, 5:30 AM

Moberg Pharma has secured exercise of warrants and entered into a top guarantee free of charge

Regulatory press release6/5/2024, 6:00 AM

The exercise period for Moberg Pharma's warrants of series 2023:1 (TO 2) begins today

Regulatory press release5/31/2024, 6:00 PM

Subscription price for Moberg Pharma's warrants of series 2023:1 (TO 2) determined

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.